The performance of BRCA1 immunohistochemistry for detecting germline, somatic, and epigenetic BRCA1 loss in high-grade serous ovarian cancer

Integrated genomic analyses of ovarian carcinoma

Debra Bell, Andrew Berchuck, Narciso Olvera et al. · Nature · 2011 · 8.2K citations · Full text

Medicine, Genetics, Oncology +14

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

M. William Audeh, James Carmichael, Richard T. Penson et al. · The Lancet · 2010 · 2.3K citations

Medicine, Gynecology, Oncology +16

Promoter Hypermethylation and BRCA1 Inactivation in Sporadic Breast and Ovarian Tumors

Manel Esteller · JNCI Journal of the National Cancer Institute · 2000 · 1.2K citations · Full text

Medicine, Genetics, Oncology +16

Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study

Karen A. Gelmon, Marc Tischkowitz, Helen Mackay et al. · The Lancet Oncology · 2011 · 1.1K citations

Medicine, Gynecology, Oncology +17

Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers

Wataru Sakai, Elizabeth M. Swisher, Beth Y. Karlan et al. · Nature · 2008 · 1.1K citations · Full text

Medicine, Genetics, Oncology +13